InventisBio (688382.SH): Phase III clinical study of Nomelcitinib (D-2570) for moderate-to-severe plaque psoriasis meets primary endpoint

InventisBio (688382.SH) announced that the registrational Phase III clinical study of nomelcitinib (D-2570), a novel orally available selective TYK2 JH2-targeting inhibitor independently developed by the company, for the treatment of moderate-to-severe plaque psoriasis met the primary endpoint and key secondary endpoints. The study results mark a milestone advancement in the clinical development of nomelcitinib (D-2570) in the field of psoriasis. During this study, nomelcitinib (D-2570) demonstrated favorable safety and tolerability, with a safety profile similar to that observed in the previous Phase II clinical study and other selective TYK2 JH2 inhibitors, and no new safety signals were identified.